Based on the argenx NV ADR stock forecast from 18 analysts, the average analyst target price for argenx NV ADR is USD 697.29 over the next 12 months. argenx NV ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of argenx NV ADR is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, argenx NV ADR’s stock price was USD 555.11. argenx NV ADR’s stock price has changed by -5.78% over the past week, -9.47% over the past month and +43.43% over the last year.
No recent analyst target price found for argenx NV ADR
No recent average analyst rating found for argenx NV ADR
Company Overview argenx NV ADR
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. Read Less
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myastheni...Read More
Frequently Asked Questions About argenx NV ADR (ARGX) Stock
Based on ratings from 18 analysts argenx NV ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 27 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ARGX's stock to indicate if its a good dividend stock.
Based on targets from 18 analysts, the average taret price for ARGX is USD 697.29 over the next 12 months. The maximum analyst target price is USD 1100 while the minimum anlayst target price is USD 553.
ARGX stock's Price/Earning ratio is 46.57.
Our analysis grades ARGX stock's Price / Earning ratio at F. This means that ARGX stock's Price/Earning ratio is above 81% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARGX may be a overvalued for its sector.
The last closing price of ARGX's stock was USD 555.11.
The most recent market capitalization for ARGX is USD 37.97B.
Based on targets from 18 analysts, the average taret price for ARGX is projected at USD 697.29 over the next 12 months.
This means that ARGX's stock price may go up by +25.61% over the next 12 months.
We can't find any ETFs which contains argenx NV ADR's stock.
As per our most recent records argenx NV ADR has 0 Employees.
argenx NV ADR's registered address is Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB.
You can get more information about it from argenx NV ADR's website at https://www.argenx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About argenx NV ADR (ARGX) Stock
Based on ratings from 18 analysts argenx NV ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 27 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ARGX's stock to indicate if its a good dividend stock.
Based on targets from 18 analysts, the average taret price for ARGX is USD 697.29 over the next 12 months. The maximum analyst target price is USD 1100 while the minimum anlayst target price is USD 553.
ARGX stock's Price/Earning ratio is 46.57.
Our analysis grades ARGX stock's Price / Earning ratio at F. This means that ARGX stock's Price/Earning ratio is above 81% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARGX may be a overvalued for its sector.
The last closing price of ARGX's stock was USD 555.11.
The most recent market capitalization for ARGX is USD 37.97B.
Based on targets from 18 analysts, the average taret price for ARGX is projected at USD 697.29 over the next 12 months.
This means that ARGX's stock price may go up by +25.61% over the next 12 months.
We can't find any ETFs which contains argenx NV ADR's stock.
As per our most recent records argenx NV ADR has 0 Employees.
argenx NV ADR's registered address is Laarderhoogtweg 25, Amsterdam, Netherlands, 1101EB.
You can get more information about it from argenx NV ADR's website at https://www.argenx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARGX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
